
Quarterly ResultAug 12, 2026, 08:41 AM
Aprea Therapeutics Q2 Cash $41.2M; APR-1051 Trial Accelerates
AI Summary
Aprea Therapeutics reported Q2 2026 financial results, including $41.2 million in cash and cash equivalents and a net loss of $3.6 million. The company announced accelerated enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor APR-1051, with plans to expand the trial to 50 patients and evaluate combination regimens. Early single-agent activity for APR-1051 was observed, and the company expects its cash to fund operations into Q1 2028.
Key Highlights
- Cash and cash equivalents were $41.2 million as of June 30, 2026.
- Operating loss for Q2 2026 was $4.0 million, compared to $3.4 million in Q2 2025.
- Net loss for Q2 2026 was $3.6 million, or $(0.07) per basic share.
- R&D expenses increased to $2.5 million in Q2 2026 from $1.9 million in Q2 2025.
- Cash and equivalents are projected to be sufficient into Q1 2028.
- Enrollment in the ACESOT-1051 trial for APR-1051 is accelerating.
- Aprea plans to expand ACESOT-1051 to include at least 50 patients.
- Next clinical data update for APR-1051 is expected in Q4 2026.
Price Impact
More from APRE
Clinical Trial1d ago, 9:06 AM
Aprea Therapeutics Reports Positive Interim Data for APR-1051 Trial
Quarterly ResultNov 4, 8:51 AM
Aprea Therapeutics Q3 Net Loss Widens to $4.81M; Cash Funds Operations into 2028
Quarterly ResultNov 4, 8:41 AM
Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028